Lulizumab pegol

Lulizumab pegol (also known as BMS-931699 or MDX-1106) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is developed by Bristol-Myers Squibb.

Mechanism of Action

Lulizumab pegol works by targeting and inhibiting the PD-1 receptor, a protein that plays a major role in suppressing the immune system. By blocking this receptor, the drug enhances the body's immune response against disease-causing cells.

Clinical Trials

Lulizumab pegol has undergone clinical trials for the treatment of various autoimmune diseases, including lupus and rheumatoid arthritis. However, as of 2020, it has not yet been approved by the FDA or any other regulatory authority.

Side Effects

Like all drugs, lulizumab pegol can cause side effects. The most common ones reported in clinical trials include fatigue, nausea, and headaches. Severe side effects can include pneumonia and other serious infections due to the drug's effect on the immune system.

See Also

• List of investigational monoclonal antibodies
• List of monoclonal antibodies

References

Lulizumab pegol Resources
Latest articles Most recent articles Ongoing trials	Wikipedia